Galectin Therapeutics Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.
Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in San Antonio, Texas, will present the data during a session titled "Parallel 8: Novel Approaches in Diagnosis and Treatment in NAFLD and NASH." Dr. Harrison is a clinical trial investigator in Galectin Therapeutics' ongoing Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis. The data presented will include the completed cohorts 1 and 2 of the Phase 1 trial and interim results of cohort 3.
According to Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc., "NASH with fibrosis is a significant unmet medical need for which effective therapies are limited. Acceptance of our data for an oral presentation at AASLD highlights the scientific and medical communities' deep interest in learning about new potential therapies for liver disease. We believe that GR-MD-02, our proprietary galectin-3 inhibitor, holds immense promise as a treatment option for fibrosis and inflammation."